ÂÜÀòÂÒÂ×

Jennifer Tousignant, JD, is Senior Vice President of Legal at Sana Biotechnology.

Jennifer has broad legal experience and leadership in the biotechnology industry working across a breadth of technologies such as small molecules, biologics, cell and gene therapies, and in the therapeutic categories of rare disease, immune-mediated disease, neurodegenerative disease, and oncology.

Jennifer joined Sana from Xilio Therapeutics where she was the Head of Legal and responsible for all legal and compliance matters, including business development, corporate governance, financings, intellectual property, litigation, quality, research and development, and transactional work. Prior to Xilio, Jennifer was Chief IP Counsel at TESARO, Inc., where she built and led the intellectual property function, was a key member of the global launch teams for Varubi, Zejula, Varuby, and the prelaunch team for Jemperli. Additionally, she played key legal roles in TESARO’s transactional work, public financings, and in its acquisition by GSK. Before TESARO, she worked at Genzyme Corporation (acquired by Sanofi) in roles of increasing responsibility, first in research and then in legal, and ultimately leading a legal team with worldwide intellectual property responsibility for products from early research to commercial, including small molecules, biologics, and gene therapy products. During her time at Genzyme, Jennifer was a member of the global launch teams for Kynamro, Cerdelga, and Lemtrada and acted as a primary counsel supporting the business development teams of the rare disease and multiple sclerosis business units.

Jennifer received her JD from Suffolk University School of Law, magna cum laude, and her BA in Chemistry with Honors from the University of Virginia.